Validation of a Set of Instruments to Assess Patient- and Caregiver-Oriented Measurements in Spinal Muscular Atrophy: Results of the SMA-TOOL Study
ConclusionsThis set of outcome measures showed adequate reliability, construct validity, and discriminant validity and may constitute a valuable option to measure symptom severity in patients with SMA. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 21, 2022 Category: Neurology Source Type: research
Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
ConclusionOnce-monthly galcanezumab significantly reduced the frequency of migraine headache days with moderate-to-severe or severe headache, migraine headache days with migraine-associated symptoms, and migraine headache days during menstrual periods in Japanese patients with episodic migraine, consistent with results from global studies.Trial Registration: ClinicalTrials.gov (NCT02959177). (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 20, 2022 Category: Neurology Source Type: research
Evaluation of Diffusion –Perfusion Mismatch in Acute Ischemic Stroke with a New Automated Perfusion-Weighted Imaging Software: A Retrospective Study
ConclusionsThe iStroke automatic processing of ADC and PWI is a reliable software for the identification of diffusion –perfusion mismatch in acute ischemic stroke. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 6, 2022 Category: Neurology Source Type: research
Integrative Analyses Identify KCNJ15 as a Candidate Gene in Patients with Epilepsy
ConclusionOur results show thatKCNJ15 may be a candidate target for epilepsy. Functional analysis ofKCNJ15 may provide novel insights for epilepsy treatment. (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 28, 2022 Category: Neurology Source Type: research
Verifynow P2Y12 PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study
ConclusionVerifynow P2Y12 PRU-guided modification of clopidogrel for ischemic stroke significantly improved or prevented recurrence at the 1-year follow-up. Our findings suggest that clopidogrel therapy based on the PRU cutoff value of 190 should be considered to improve outcomes.Trial RegistrationClinicalTrials.gov NCT02618265 (December 1, 2015). (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 26, 2022 Category: Neurology Source Type: research
Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
ConclusionPatients newly initiated on teriflunomide and fingolimod had better real-world persistence and adherence at 6 and 12 months, and longer time to switch to higher-cost therapies, than patients on dimethyl fumarate or diroximel fumarate. (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 24, 2022 Category: Neurology Source Type: research
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial
ConclusionThis prespecified analysis of data from MONONOFU has confirmed that the efficacy of lasmiditan is rapid in onset and sustained in patients with moderate-to-severe migraine in Japan.Trial RegistrationClinicalTrials.gov (NCT03962738). (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 22, 2022 Category: Neurology Source Type: research
Elderly-Onset Paroxysmal Kinesigenic Dyskinesia: A Case Report
AbstractParoxysmal kinesigenic dyskinesia (PKD) is characterized by transient and recurrent involuntary movements that are triggered by a sudden movement. Here, we report an elderly female patient with a 1-month history of paroxysmal rigidity of the right limb. As the symptoms were characterized as paroxysmal, transient, and repetitive, her condition was initially thought to be epilepsy. Subsequent examinations showed no abnormality in the continuous video-electroencephalogram (EEG) monitoring, magnetic resonance imaging (MRI), fluorodeoxyglucose (FDG) –positron emission tomography (PET)/computed tomography (CT), and gen...
Source: Neurology and Therapy - September 17, 2022 Category: Neurology Source Type: research
Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study
ConclusionBrivaracetam was effective and well tolerated both as first add-on and late adjunctive treatment in patients with focal epilepsy. (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 16, 2022 Category: Neurology Source Type: research
Expert-Agreed Practical Recommendations on the Use of Cladribine
This article gathers their practical recommendations to aid treatment decision-making and optimise the use of cladribine tablets in patients with RMS. The consensus recommendations cover the following areas: candidate patient profiles, switching strategies (to and from cladribine), managing response to cladribine and safety considerations. (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 6, 2022 Category: Neurology Source Type: research
Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations
ConclusionThe primary goal of the recommended dose reductions of concomitant ASMs is to prevent or resolve adverse effects, thereby allowing cenobamate to reach the optimal dose to achieve the maximal potential of improving seizure control. (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 3, 2022 Category: Neurology Source Type: research
Circulating Insulin-Like Growth Factor 1 Levels and Migraine Risk: A Mendelian Randomization Study
ConclusionThis two-sample Mendelian randomization study showed that genetically determined increased IGF1 levels are causally associated with decreased migraine risk. Future randomized controlled trials are warranted to confirm the benefits of IGF1 administration on migraines. (Source: Neurology and Therapy)
Source: Neurology and Therapy - September 1, 2022 Category: Neurology Source Type: research
COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study
ConclusionDespite their personal experience of reduced frequency of infection since immune medication was initiated, patients with CIDP or MMN reported increased risk perception and prevalence of depressive symptoms, generalized anxiety, and COVID-19-related fear in comparison to healthy controls. This highlights the need for evidence-driven strategies to protect the mental health of this vulnerable group. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
AbstractMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton ’s tyrosine kinase inhibitors, anti-apoptotic ...
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies
ConclusionsThis targeted literature search and phenomenological review confirms PwMS preferences for empowered decision-making in disease management and treatment selection, to optimize independence, safety, and efficacy. It also identifies an unmet need for improved communication and information tools that convey MS information in a relatable manner. Furthermore, this review seeks to address this unmet need by providing plain language figures and descriptions of MS immune mechanisms that can be used to facilitate discussions between HCPs and PwMS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - July 30, 2022 Category: Neurology Source Type: research
